Fortrea will release its 2025 financial results on February 26, 2026, and hold an earnings call at 8:00 am ET.
Quiver AI Summary
Fortrea, a prominent global contract research organization, announced that it will disclose its fourth-quarter and full-year financial results for 2025 on February 26, 2026, before the market opens. Following the release, the company will conduct a conference call at 8:00 am ET to discuss the results and answer questions, with participants encouraged to register in advance on the Fortrea Investor Relations website. A webcast of the call will be made available, and a replay will be accessible after the event. Fortrea specializes in providing clinical development solutions across various therapeutic areas and collaborates with biopharmaceutical, biotechnology, and medical device companies to advance healthcare innovation globally.
Potential Positives
- Fortrea is scheduled to release its fourth quarter and full year 2025 financial results, providing transparency and regular updates to investors.
- The company will host a conference call to discuss its financial results, allowing for direct engagement with stakeholders through a question-and-answer session.
- Fortrea's status as a leading global contract research organization highlights its significant role in the life sciences industry and its commitment to healthcare innovation.
- The company's extensive experience across more than 20 therapeutic areas reinforces its credibility and capacity to deliver critical clinical development solutions.
Potential Negatives
- None
FAQ
When will Fortrea release its 2025 financial results?
Fortrea will release its fourth quarter and full year 2025 financial results on February 26, 2026.
How can I participate in the Fortrea earnings call?
Participants can register online at the Fortrea Investor Relations website to join the earnings call.
What time is the Fortrea conference call scheduled?
The conference call is scheduled for 8:00 am ET on February 26, 2026.
Where can I find the replay of the earnings call?
A replay of the earnings call will be available on the Fortrea Investor Relations website shortly after the event.
What services does Fortrea offer in clinical development?
Fortrea provides phase I-IV clinical trial management, clinical pharmacology, and consulting services to life sciences companies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FTRE Insider Trading Activity
$FTRE insiders have traded $FTRE stock on the open market 10 times in the past 6 months. Of those trades, 3 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $FTRE stock by insiders over the last 6 months:
- PETER M NEUPERT has made 2 purchases buying 62,500 shares for an estimated $407,150 and 0 sales.
- ERIN L RUSSELL purchased 9,854 shares for an estimated $100,018
- ROBERT PARKS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 7,930 shares for an estimated $79,069.
- JILL G. MCCONNELL (Chief Financial Officer) has made 0 purchases and 2 sales selling 8,042 shares for an estimated $71,422.
- MARK A. MORAIS (Chief Operating Officer) has made 0 purchases and 2 sales selling 8,041 shares for an estimated $71,412.
- JAMES S. HANSON (General Counsel) sold 1,677 shares for an estimated $17,155
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FTRE Revenue
$FTRE had revenues of $701.3M in Q3 2025. This is an increase of 3.91% from the same period in the prior year.
You can track FTRE financials on Quiver Quantitative's FTRE stock page.
$FTRE Hedge Fund Activity
We have seen 144 institutional investors add shares of $FTRE stock to their portfolio, and 173 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC removed 2,779,641 shares (-42.7%) from their portfolio in Q3 2025, for an estimated $23,404,577
- STARBOARD VALUE LP removed 2,495,558 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,012,598
- PARK WEST ASSET MANAGEMENT LLC added 2,206,556 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,579,201
- NUVEEN, LLC added 1,519,622 shares (+507.3%) to their portfolio in Q3 2025, for an estimated $12,795,217
- COLISEUM CAPITAL MANAGEMENT, LLC removed 1,227,065 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,331,887
- EAGLE HEALTH INVESTMENTS LP added 988,772 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,325,460
- DEUTSCHE BANK AG\ added 920,670 shares (+56.6%) to their portfolio in Q3 2025, for an estimated $7,752,041
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FTRE Analyst Ratings
Wall Street analysts have issued reports on $FTRE in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 01/06/2026
- Citigroup issued a "Buy" rating on 12/11/2025
- Baird issued a "Outperform" rating on 09/03/2025
To track analyst ratings and price targets for $FTRE, check out Quiver Quantitative's $FTRE forecast page.
$FTRE Price Targets
Multiple analysts have issued price targets for $FTRE recently. We have seen 8 analysts offer price targets for $FTRE in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Charles Rhyee from TD Cowen set a target price of $15.0 on 01/22/2026
- Jailendra Singh from Truist Securities set a target price of $22.0 on 01/08/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $25.0 on 01/06/2026
- Ann Hynes from Mizuho set a target price of $13.0 on 12/18/2025
- Luke Sergott from Barclays set a target price of $15.0 on 12/15/2025
- Patrick Donnelly from Citigroup set a target price of $21.0 on 12/11/2025
- David Windley from Jefferies set a target price of $9.5 on 09/09/2025
Full Release
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.
To participate in the earnings call, participants should register online at the Fortrea Investor Relations website . To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link .
A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea Investor Relations website.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts
Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]
